Avid Bioservices Inc (CDMO)

[Ando Financing Firm]

We have had a lot of good news this month. I am surprised so many sells after this news raised price:

Peregrine Pharmaceuticals Research Report
On June 3, 2013, Peregrine Pharmaceuticals, Inc. (Peregrine Pharmaceuticals) reported that data was presented at the 2013 ASCO (American Society of Clinical Oncology) Meeting from two clinical trials evaluating the Company's lead clinical candidate bavituximab, a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Interim data from a Phase I trial, evaluating bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer (MBC), showed that 85% of patients were able to achieve objective tumor response, with 15% of patients achieving a complete response (CR) in accordance to Response Evaluation Criteria in Solid Tumors (RECIST). Further, the Company reported that in the second study, results from a randomized Phase II trial of bavituximab plus gemcitabine in patients with non-resectable Stage IV pancreatic cancer demonstrated more than a doubling of the overall response rate (ORR) and an improvement in overall survival (OS), including a delayed separation in the Kaplan-Maeier survival curve that is commonly seen in promising cancer immunotherapies. The Full Research Report on Peregrine Pharmaceuticals - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/df4a_PPHM]